Testing a biosimilar of Taltz in healthy adults
Treatments studied
This study tests a biosimilar version of Taltz (SB35) against the original in healthy adults. It checks how the drug is absorbed and if it is safe, without causing serious side effects, helping to ensure the biosimilar works the same way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult between 19 and 55 years old.
- Your weight must be between 55 and 90 kg (about 121 to 198 lbs) with a BMI between 20 and 30.
- You must not have any significant medical conditions, including serious allergies, inflammatory bowel disease, tuberculosis, or a history of cancer.
- You must not have taken Taltz (ixekizumab) or a similar biologic medicine before.
- You must agree to use effective birth control during the study and for 10 weeks after.
- You must be a non-smoker (or have not smoked in the last 6 months) and avoid heavy alcohol use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 study tests an experimental drug called TIX100 in healthy volunteers to check its safety and how the body processes it. The results will help determine if the drug can be studied in future trials for conditions like obesity or metabolic disorders.
This study tests a new investigational medicine in healthy adults to see how safe it is and how the body processes it. It is a first-in-human trial, so it is looking for volunteers who are generally well and have normal immune function.
This study is testing a new medicine called mirikizumab in healthy people to see how it works in the body. Healthy volunteers help researchers understand the drug's safety before it is studied in patients with a disease.
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
This study tests a new investigational drug called ISH0613 in healthy volunteers to see if it is safe and how the body processes it. It is the first time this drug is given to humans.
This study tests a new medicine (INCA033989) given as a shot or IV in healthy adults to see how the body processes it and if it's safe.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.